InvestorsHub Logo
Followers 7
Posts 1173
Boards Moderated 0
Alias Born 11/13/2018

Re: MontanaState83 post# 214438

Sunday, 09/15/2019 8:05:11 AM

Sunday, September 15, 2019 8:05:11 AM

Post# of 425670
You need to look at the recommendations from the different organizations and the marks that reduce-it is getting. Just this weekend NLA gave it a Class I recommendation. The other organizations have also given the trial design and recommendations very high marks. They do not believe that mineral oil has tainted the trial results. All of these organizations will come out in support of Amarin and Vascepa at the AdCom. Hell, the FDA will come out in support of Amarin at the AdCom. They are the ones that approved the trial and asked for Amarin to proceed with this Cardiovascular outcomes trial. Remember the results are far better than anyone thought. The only people still saying that the results are too good to be true are those without scientific backgrounds. They have to make a lot of noise but no one is going to believe them. MRC tried his M.O. arguments with ICER and got nowhere. NONE of the analyst are saying that the AdCom is going to go against Vascepa.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News